Data Insights

Defactinib hydrochloride by Verastem for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Defactinib hydrochloride by Verastem for Pancreatic Cancer: Likelihood of Approval

Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Pancreatic Cancer

Data Insights

Avutometinib potassium by Verastem for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Avutometinib potassium by Verastem for Metastatic Pancreatic Cancer: Likelihood of Approval

Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Metastatic Pancreatic Cancer

Data Insights

Defactinib hydrochloride by Verastem for Metastatic Melanoma: Likelihood of Approval

Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Metastatic Melanoma

Data Insights

Avutometinib potassium by Verastem for Metastatic Melanoma: Likelihood of Approval

Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Metastatic Melanoma

Data Insights

Defactinib hydrochloride by Verastem for Colorectal Cancer: Likelihood of Approval

Defactinib hydrochloride is under clinical development by Verastem and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Colorectal Cancer

Data Insights

Avutometinib potassium by Verastem for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Avutometinib potassium by Verastem for Fallopian Tube Cancer: Likelihood of Approval

Avutometinib potassium is under clinical development by Verastem and currently in Phase III for Fallopian Tube Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Fallopian Tube Cancer

Data Insights

Defactinib hydrochloride by Verastem for Metastatic Uveal Melanoma: Likelihood of Approval

Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Metastatic Uveal Melanoma

Data Insights

Defactinib hydrochloride by Verastem for Peritoneal Cancer: Likelihood of Approval

Defactinib hydrochloride is under clinical development by Verastem and currently in Phase III for Peritoneal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Peritoneal Cancer

Data Insights

Defactinib hydrochloride by Verastem for Fallopian Tube Cancer: Likelihood of Approval

Defactinib hydrochloride is under clinical development by Verastem and currently in Phase III for Fallopian Tube Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Fallopian Tube Cancer

Data Insights

Avutometinib potassium by Verastem for Cervical Cancer: Likelihood of Approval

Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Cervical Cancer

Data Insights

Avutometinib potassium by Verastem for Papillary Thyroid Cancer: Likelihood of Approval

Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Papillary Thyroid Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Papillary Thyroid Cancer

Data Insights

Avutometinib potassium by Verastem for Anaplastic Thyroid Cancer: Likelihood of Approval

Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Anaplastic Thyroid Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Anaplastic Thyroid Cancer

Data Insights

Avutometinib potassium by Verastem for Follicular Thyroid Cancer: Likelihood of Approval

Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Follicular Thyroid Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Follicular Thyroid Cancer

Data Insights

Avutometinib potassium by Verastem for Metastatic Uveal Melanoma: Likelihood of Approval

Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Metastatic Uveal Melanoma

Data Insights

Avutometinib potassium by Verastem for Peritoneal Cancer: Likelihood of Approval

Avutometinib potassium is under clinical development by Verastem and currently in Phase III for Peritoneal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Peritoneal Cancer

Data Insights

Defactinib hydrochloride by Verastem for Ovarian Cancer: Likelihood of Approval

Defactinib hydrochloride is under clinical development by Verastem and currently in Phase III for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Ovarian Cancer

Data Insights

Avutometinib potassium by Verastem for Ovarian Cancer: Likelihood of Approval

Avutometinib potassium is under clinical development by Verastem and currently in Phase III for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Ovarian Cancer